UY25334A1 - Tiazol derivados - Google Patents
Tiazol derivadosInfo
- Publication number
- UY25334A1 UY25334A1 UY25334A UY25334A UY25334A1 UY 25334 A1 UY25334 A1 UY 25334A1 UY 25334 A UY25334 A UY 25334A UY 25334 A UY25334 A UY 25334A UY 25334 A1 UY25334 A1 UY 25334A1
- Authority
- UY
- Uruguay
- Prior art keywords
- cell
- formula
- aralkyl
- alkyl
- well
- Prior art date
Links
- -1 3-benzyl-ureido Chemical group 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000008619 cell matrix interaction Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000008611 intercellular interaction Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000005748 tumor development Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de fórmula I (como por ejemplo ácido ra 3-[2-[[(2-(3-bencil-ureido)-tiazol-4-ilcarbonil]-amino]-acetalamino]-3-fenil-propionico) así como sus sales y ésteres farmacéuticamente utilizables, en donde R1 se elije dentro del grupo de fórmula 2, R2 es un compuesto de fórmula lll y R3 se selecciona entre H, alquilo, cicloalquilo, arilo, aralquilo, heteroarilo carboxilo, alquilo o aralquilo; a es 0 o números enteros positivos, siendo a 0 a 2, pero no siendo 0 cuando R1 es NH2; inhiben la unión de proteinas adhesivas a la superficie de diferentes tipos de célula y por consiguiente influencian interacciones de célula - célula y célula - matriz. Pueden utilizarse en forma de preparados farmacéuticos para el control o prevención de neoplasmas, mestastasis tumoral, desarrollo tumoral, osteoporosis, enfermedad de Paget, retinopatía diabética, degeneración macular, restenosis después de intervención vascular, psoriasis, artritis, fibrosis, insuficiencia renal, así como infecciones causadas por virus, bacterias u hongos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98100006 | 1998-01-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25334A1 true UY25334A1 (es) | 2001-01-31 |
Family
ID=8231229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25334A UY25334A1 (es) | 1998-01-02 | 1998-12-31 | Tiazol derivados |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US6100282A (es) |
| JP (1) | JP3113237B2 (es) |
| KR (1) | KR100312901B1 (es) |
| CN (1) | CN1080720C (es) |
| AR (1) | AR014949A1 (es) |
| AT (1) | ATE233746T1 (es) |
| AU (1) | AU720618B2 (es) |
| BR (1) | BR9900006A (es) |
| CA (1) | CA2257328C (es) |
| CO (1) | CO4990934A1 (es) |
| DE (1) | DE69811844T2 (es) |
| DK (1) | DK0928790T3 (es) |
| ES (1) | ES2193471T3 (es) |
| HK (1) | HK1020953A1 (es) |
| HR (1) | HRP980645A2 (es) |
| HU (1) | HUP9803040A3 (es) |
| ID (1) | ID21936A (es) |
| IL (1) | IL127785A (es) |
| MA (1) | MA26591A1 (es) |
| NO (1) | NO312067B1 (es) |
| NZ (2) | NZ333590A (es) |
| PE (1) | PE20000061A1 (es) |
| PL (1) | PL330619A1 (es) |
| PT (1) | PT928790E (es) |
| RU (1) | RU2218337C2 (es) |
| SG (1) | SG74686A1 (es) |
| TR (1) | TR199802765A2 (es) |
| UY (1) | UY25334A1 (es) |
| YU (1) | YU61398A (es) |
| ZA (1) | ZA9811925B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| GB9826174D0 (en) * | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
| US6759425B2 (en) * | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| NZ520143A (en) * | 2000-01-19 | 2005-01-28 | Alteon Inc | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
| DK1368028T3 (da) * | 2001-03-12 | 2007-12-27 | Avanir Pharmaceuticals | Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering |
| PE20030968A1 (es) * | 2002-02-28 | 2004-01-12 | Novartis Ag | Derivados de 5-feniltiazol como inhibidores de cinasas |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| EP1651198A2 (en) * | 2003-08-08 | 2006-05-03 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| EA012607B1 (ru) * | 2004-09-20 | 2009-10-30 | 4Сц Аг | НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB |
| WO2008011191A1 (en) * | 2006-07-21 | 2008-01-24 | Replidyne, Inc. | Antibacterial heterocyclic ureas |
| US8293919B2 (en) * | 2007-07-23 | 2012-10-23 | Crestone, Inc. | Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds |
| EP2200440B1 (en) | 2007-07-23 | 2017-07-19 | Crestone, Inc. | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds |
| TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| CN102936257B (zh) * | 2012-08-30 | 2016-03-30 | 齐鲁工业大学 | 一类含银的噻唑西弗碱配合物的结构、制备和用途 |
| US20200123147A1 (en) | 2017-06-29 | 2020-04-23 | Bayer Aktiengesellschaft | Thiazole compounds useful as prmt5 inhibitors |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2009155B (en) * | 1977-11-07 | 1982-07-21 | Leo Pharm Prod Ltd | Chemical compounds |
| FR2581063B1 (fr) * | 1985-04-30 | 1987-07-17 | Chauvin Blache Lab | Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique |
| JPS62123180A (ja) * | 1985-11-21 | 1987-06-04 | Otsuka Pharmaceut Factory Inc | ｐ−アミノフエノ−ル誘導体 |
| US5000775A (en) * | 1985-12-31 | 1991-03-19 | Monsanto Company | 2-amino-4,5-disubstituted-oxazole/thiazole compounds as herbicide antidotes |
| JPS6348873A (ja) * | 1986-08-19 | 1988-03-01 | Toshiba Corp | ガスレ−ザ発振装置 |
| CA2037153A1 (en) * | 1990-03-09 | 1991-09-10 | Leo Alig | Acetic acid derivatives |
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| FI922867A (fi) * | 1991-06-21 | 1992-12-22 | Tanabe Seiyaku Co | Dikarbonsyraderivat och foerfarande foer framstaellning av dem |
| AU646966B2 (en) * | 1991-08-23 | 1994-03-10 | Takeda Chemical Industries Ltd. | 2-piperazinone compounds, their production and use |
| GB9125970D0 (en) * | 1991-12-06 | 1992-02-05 | Fujisawa Pharmaceutical Co | New compounds |
| US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| JPH08337579A (ja) * | 1995-06-14 | 1996-12-24 | Fujisawa Pharmaceut Co Ltd | グアニジノチアゾ−ルおよびその抗潰瘍剤、ｈ２−受容体拮抗剤および抗菌剤としての用途 |
| JPH09295974A (ja) * | 1995-09-11 | 1997-11-18 | Nippon Nohyaku Co Ltd | アゾール誘導体、その用途及びその製造方法並びにその使用方法 |
| AU679887B2 (en) * | 1995-09-11 | 1997-07-10 | Nihon Nohyaku Co., Ltd. | Azole derivatives, their use, production and usage |
| JP4327249B2 (ja) * | 1995-12-29 | 2009-09-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗ヘルペスウイルス性を有するフェニルチアゾール誘導体 |
| MA26487A1 (fr) * | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
-
1998
- 1998-12-22 US US09/218,567 patent/US6100282A/en not_active Expired - Fee Related
- 1998-12-24 AT AT98124670T patent/ATE233746T1/de not_active IP Right Cessation
- 1998-12-24 NZ NZ333590A patent/NZ333590A/xx unknown
- 1998-12-24 ES ES98124670T patent/ES2193471T3/es not_active Expired - Lifetime
- 1998-12-24 DE DE69811844T patent/DE69811844T2/de not_active Expired - Fee Related
- 1998-12-24 PT PT98124670T patent/PT928790E/pt unknown
- 1998-12-24 DK DK98124670T patent/DK0928790T3/da active
- 1998-12-24 NZ NZ333591A patent/NZ333591A/xx unknown
- 1998-12-28 NO NO19986159A patent/NO312067B1/no unknown
- 1998-12-29 HR HR98100006.0A patent/HRP980645A2/hr not_active Application Discontinuation
- 1998-12-29 AR ARP980106723A patent/AR014949A1/es not_active Application Discontinuation
- 1998-12-29 IL IL12778598A patent/IL127785A/en not_active IP Right Cessation
- 1998-12-29 ZA ZA9811925A patent/ZA9811925B/xx unknown
- 1998-12-29 PE PE1998001293A patent/PE20000061A1/es not_active Application Discontinuation
- 1998-12-30 SG SG1998005978A patent/SG74686A1/en unknown
- 1998-12-30 YU YU61398A patent/YU61398A/sh unknown
- 1998-12-30 CA CA002257328A patent/CA2257328C/en not_active Expired - Fee Related
- 1998-12-30 AU AU96144/98A patent/AU720618B2/en not_active Ceased
- 1998-12-30 TR TR1998/02765A patent/TR199802765A2/xx unknown
- 1998-12-30 HU HU9803040A patent/HUP9803040A3/hu unknown
- 1998-12-30 PL PL98330619A patent/PL330619A1/xx not_active Application Discontinuation
- 1998-12-30 MA MA25411A patent/MA26591A1/fr unknown
- 1998-12-30 CO CO98077476A patent/CO4990934A1/es unknown
- 1998-12-31 CN CN98125982A patent/CN1080720C/zh not_active Expired - Fee Related
- 1998-12-31 KR KR1019980063364A patent/KR100312901B1/ko not_active IP Right Cessation
- 1998-12-31 UY UY25334A patent/UY25334A1/es not_active IP Right Cessation
-
1999
- 1999-01-04 ID IDP990001D patent/ID21936A/id unknown
- 1999-01-04 BR BR9900006-7A patent/BR9900006A/pt not_active Application Discontinuation
- 1999-01-04 JP JP11000010A patent/JP3113237B2/ja not_active Expired - Fee Related
- 1999-01-05 RU RU99100277/04A patent/RU2218337C2/ru not_active IP Right Cessation
- 1999-12-28 HK HK99106136A patent/HK1020953A1/xx not_active IP Right Cessation
-
2000
- 2000-03-15 US US09/526,033 patent/US6320054B1/en not_active Expired - Fee Related
-
2001
- 2001-06-11 US US09/878,704 patent/US6344562B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25334A1 (es) | Tiazol derivados | |
| AR024703A1 (es) | Benzazepinonas y quinazolinas | |
| PT74390A (fr) | Nouveaux acides 2-<4-(diphenylmethyl)-1-piperazinyl>-acetiques et leurs amides leurs procedes de preparation et compositions therapeutiques | |
| WO2008154484A1 (en) | Ire-1a inhibitors | |
| Engman et al. | Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells | |
| AR023058A1 (es) | Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos | |
| DK1663970T3 (da) | Matrixmetalloproteinaseinhibitorer | |
| CN103347516A (zh) | 新的基质金属蛋白酶抑制剂 | |
| UY25335A1 (es) | Tiazol derivados | |
| US6239277B1 (en) | Process for preparing piperazine-substituted aliphatic carboxylates | |
| US3882237A (en) | 2-(substituted-methyl)-5,6-dihydro-1,4-oxathiin-3-carboxamides used as fungicides | |
| ECSP982811A (es) | Derivados de tiazol | |
| WO2017220302A1 (de) | Enzymstabilisatoren | |
| ECSP993185A (es) | Derivados de tiazol | |
| EA199901034A3 (ru) | Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы | |
| Foye et al. | Antiradiation compounds. 20. 1-Methylquinolinium (and pyridinium)-2-dithioacetic acid derivatives | |
| ECSP982810A (es) | Derivados de tiazol | |
| Veerendhar et al. | Synthesis of enantiomeric aminoalkylcarbamoylphosphonates and their evaluation as dual‐action anticancer MMP and carbonic anhydrase inhibitors | |
| ECSP055546A (es) | Derivados novedosos de piridiletanol (feniletil) aminas como inhibidores de la biosíntesis de colesterol, procesos para su preparación, y composiciones farmaceuticas que los contienen | |
| US3646029A (en) | Piperazino methyl 1 3 diarylguandines | |
| AR013661A1 (es) | Derivados de tiourea o sus sales no toxicas para inhibir el desarrollo de celulas ras-transformadas | |
| BR0012324A (pt) | Preparação de derivados de 2-(2-arilmorfolin-2-il)etanol e intermediário | |
| AU2007285937A1 (en) | Thiourea compounds | |
| AR029304A1 (es) | DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS | |
| TH57858B (th) | อนุพันธ์ของไทอะโซล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| VENC | Patent expired |
Effective date: 20181231 |